Theralase identifies “superpotent anti-cancer drugs”
Theralase Technologies Inc. has identified a new platform of “superpotent anti-cancer drugs.” The PDCs are apparently 10 billion times more potent in killing cancer cells than other tested PDCs.
THERALASE TECHNOLOGIES Inc. has recently identified a new platform of superpotent anti-cancer drugs, or PDCs, discovered by Dr. Sherri McFarland, PhD, professor, department of chemistry and biochemistry, University of North Carolina at Greensboro, the original inventor of the Theralase licensed ruthenium-based PDCs.
Dr. McFarland has discovered a new generation of PDCs, that are 10 billion times more potent in killing cancer cells than other tested PDCs. It only takes a few molecules of the new PDCs to kill cancer cells, in vitro, when activated by visible light.
The new PDCs also exhibit very low, in vitro, dark cytotoxicity (cancer cell kill in the absence of light), providing a very low toxicity to cells.
This photocytotoxicity (cancer cell kill in the presence of light) activity has been optimized, without increasing the dark cytotoxicity.
These next-generation PDCs are thus able to increase in vitro therapeutic margins (ability to kill cancer cells when light activated versus when not light activated) by 10 orders of magnitude over tested PDCs and were conceived by Dr. McFarland by designing the most potent PDCs for systemic (intravenous or IV) patient administration at the lowest possible dose.
The preliminary data, obtained to date, demonstrate that the new PDCs exhibit preferential properties for IV delivery and are thus able to greatly expand the scope of cancers that can be targeted by this new platform PDT technology.
Dr. McFarland stated that: “I am delighted that we have discovered new PDCs that are able to increase the photodynamic therapy (PDT) potency over other tested PDCs by 10 orders of magnitude (10 billion times), using highly specialized methodologies and formulations. The very large and unprecedented therapeutic margins make safe, IV systemic delivery of these new PDCs that much more possible, vastly increasing the number of cancers that can be targeted with this
PDT technology. With our PDC TLD-1433 showing promise in a phase Ib clinical trial for treating non-muscle invasive bladder cancer (NMIBC) with PDT, it is an exciting time to be working closely with the Theralase team on the development of the next-generation PDCs for hard-to-treat cancers such as glioblastoma multiforme (GBM), a deadly form of brain cancer.”
Dr. Arkady Mandel, MD, PhD, DSc, chief scientific officer of Theralase, stated that: “The ability to increase the light toxicity of the PDC by 10 orders of magnitude without affecting the dark toxicity of the PDC, is a dramatic discovery. The in vitro results presented by Dr. McFarland opens up a tremendous opportunity to develop and clinically evaluate a new PDT technology platform that may mitigate the risk of systemic toxicity, while offering an exceptional potency in the destruction of cancer cells; hence, safely and effectively, destroying a greater quantity of cancer cells per single treatment. This provides the company with an opportunity to establish a new realm in the types of cancers that can safely and effectively be treated with this cutting-edge PDT technology.”
Roger Dumoulin-White, PEng, president and chief executive officer of Theralase, stated that: “Theralase, in its collaborative research partnership with Dr. McFarland, continues to push the envelope on what these PDCs are capable of in the destruction of cancer cells. I look forward to scaling up the manufacture of these new PDCs to allow use in a new phase Ib clinical study.”
About Theralase Technologies Inc.
Theralase Technologies in its therapeutic laser technology (TLT) division designs, manufactures, markets and distributes patented super-pulsed laser technology indicated for the treatment of chronic knee pain, and in off-label use, the elimination of pain, reduction of inflammation and dramatic acceleration of tissue healing for numer ous nerve, mus cle an d joint conditions. Theralase’s photodynamic therapy (PDT) division researches and develops specially designed molecules called photodynamic compounds (PDCs), which have demonstrated an ability to localize to cancer cells and then when laser light activated, effectively destroy them.
We seek Safe Harbor.
Guy John Anderson, Randall Bruder, Roger John Dumoulin-White, Matthew Thomas Perraton
(TLT) Shares: 126,481,526